AP Biosciences (ROCO:6945) Total Assets: NT$1,365.33 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6945 AP Biosciences Inc ROCO:6945
14 GF Score
Price NT$106.50
! 1 Warning Sign
View Full Analysis

What is AP Biosciences Total Assets?

AP Biosciences ROCO:6945 -1.39% 14 Total Assets is NT$1,365.33 Mil as of Dec. 2025. GuruFocus rates ROCO:6945 with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

AP Biosciences's Total Assets for the quarter that ended in Dec. 2025 was NT$1,365.33 Mil.

During the past 12 months, AP Biosciences's average Total Assets Growth Rate was 4.80% per year. During the past 3 years, the average Total Assets Growth Rate was 99.60% per year. During the past 5 years, the average Total Assets Growth Rate was 365.80% per year.

During the past 6 years, AP Biosciences's highest 3-Year average Total Assets Growth Rate was 1829.00%. The lowest was 99.60%. And the median was 102.80%.

Total Assets is connected with ROA %. AP Biosciences's annualized ROA % for the quarter that ended in Dec. 2025 was -26.59%. Total Assets is also linked to Revenue through Asset Turnover. AP Biosciences's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.


AP Biosciences  (ROCO:6945) Total Assets Explanation

Total Assets is connected with ROA %.

AP Biosciences's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-376.352/( (1464.985+1365.33)/ 2 )
=-376.352/1415.1575
=-26.59 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

AP Biosciences's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0/( (1464.985+1365.33)/ 2 )
=0/1415.1575
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

AP Biosciences Total Assets Related Terms


AP Biosciences Total Assets Historical Data

* Premium members only.

The historical data trend for AP Biosciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AP Biosciences Total Assets Chart

AP Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 579.35 1,103.18 890.76 1,727.14 1,365.33

AP Biosciences Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 1,727.14 1,548.51 1,464.99 1,365.33
ROCO:6945
14GF Score
AP Biosciences Inc ROCO:6945
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AP Biosciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

AP Biosciences's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=1271.108+94.222
=1,365.33

AP Biosciences's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=1271.108+94.222
=1,365.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of NT$1,365.33 Mil mean?
AP Biosciences (ROCO:6945) has a Total Assets of NT$1,365.33 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on AP Biosciences and its competitors.
Is AP Biosciences' Total Assets too high?
AP Biosciences' current Total Assets is NT$1,365.33 Mil. Overall, AP Biosciences has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AP Biosciences' Total Assets compare to VRTX and REGN?
AP Biosciences' Total Assets of NT$1,365.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on AP Biosciences and its competitors. AP Biosciences's current Total Assets is NT$1,365.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AP Biosciences stock overvalued right now?
AP Biosciences (ROCO:6945) has a current Total Assets of NT$1,365.33 Mil. The current Total Assets is NT$1,365.33 Mil. AP Biosciences' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For AP Biosciences (ROCO:6945), the current Total Assets is NT$1,365.33 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AP Biosciences Business Description

Address No. 3, Park Street, 17th Floor, Taipei, TWN
AP Biosciences Inc is a clinical-stage bispecific antibody new drug research and development company. It has developed a series of antibody and protein lead drugs through a self-designed technology platform for unmet medical needs, focusing on Specific targets associated with diseases to deliver safe, effective and cost-effective medicines.
14GF Score

Get the complete analysis for ROCO:6945

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$106.50
Price